Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2016 07:00 ET | Source: Curis, Inc

Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association

LEXINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
June 02, 2016 07:15 ET | Source: Curis, Inc.

Curis to Present at the Jefferies Healthcare Conference

LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
June 02, 2016 07:00 ET | Source: Curis, Inc.

Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting

LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
June 01, 2016 07:00 ET | Source: Curis, Inc.

Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints

LEXINGTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
May 09, 2016 08:00 ET | Source: Curis, Inc.

Curis Reports First Quarter 2016 Financial Results

LEXINGTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
May 02, 2016 07:00 ET | Source: Curis, Inc.

Curis to Release First Quarter 2016 Financial Results and Hold Conference Call on May 9, 2016

LEXINGTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for...
April 20, 2016 09:00 ET | Source: Curis, Inc.

Curis and Aurigene Present Preclinical Data from Multiple Programs at AACR Annual Meeting

LEXINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug...
April 11, 2016 07:00 ET | Source: Curis, Inc.

Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting

LEXINGTON, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
April 04, 2016 07:00 ET | Source: Curis, Inc.

Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

-- Latest analysis of data presented at the American Society of Hematology’s annual meeting in December, 2015 ---- CUDC-907 demonstrated objective responses, including complete responses, in...
March 30, 2016 07:00 ET | Source: Curis, Inc.

Curis Announces Expansion of Executive Team

-- James Dentzer joins Curis as Chief Financial and Chief Administrative Officer ---- David Tuck, M.D. is promoted to Chief Medical Officer and Mani Mohindru, Ph.D. is promoted to Chief Strategy...